Company intelligence / Profile preview
Theialife Sciences
- Ownership
- Private
- Development stage
- Phase 3
Overview
Theialife's lead program ND10/7MX is the world's first clinical phase III-ready oral therapy for pediatric myopia. It has completed preclinical and phase II trials with over a decade of real-world use in Denmark (~1200 children treated), showing safety and efficacy with no reported adverse effects. Data published in the British Journal of Ophthalmology supports its effectiveness in children aged 6–11 at risk of high myopia progression. Global phase III trials are set to begin soon.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules (notably oral therapeutics)Extended-release formulationsNovel molecular platforms for ophthalmic diseases
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Theialife Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theialife Sciences.